Screening for neurotoxic amino acid associated with neurological disorders
Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.
1. A method of screening a subject comprising analyzing a keratinous tissue sample from the subject to determine the presence of protein-bound β-N-methylamino-L-alanine (BMAA) or 2,4-diaminobutyrate.
2. The method of claim 1 , wherein the tissue sample is analyzed for protein-bound BMAA.
3. The method of claim 1 , wherein protein-bound 2,4-diaminobutyrate is analyzed.
4. The method of claim 1 , further wherein free BMAA or 2,4-diaminobutyrate is analyzed.
5. The method of claim 1 , wherein the keratinous tissue is selected from the group consisting of hair, skin, nail, fingernail, toenail, feather, claw, hoof and horn.
6. The method of claim 5 , wherein the keratinous tissue is hair.
7. The method of claim 5 , wherein the keratinous tissue is selected from the group consisting of nail, fingernail and toenail.
8. The method of claim 5 , wherein the keratinous tissue is skin.
9. The method of claim 8 , wherein the skin is a skin biopsy.
10. A method of screening a subject comprising analyzing a tissue sample from the subject to determine the presence of protein-bound β-N-methylamino-L-alanine (BMAA) or 2,4-diaminobutyrate, wherein the tissue is saliva or urine.
11. A method of screening a subject comprising analyzing a tissue sample from the subject to determine the presence of β-N-methylamino-L-alanine (BMAA) or 2,4-diaminobutyrate, wherein protein-bound BMAA or 2,4-diaminobutyrate is analyzed.